Editas Medicine Announces Third Quarter 2026 Results and Business Updates

On November 9, 2026 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, reported financial results for the third quarter 2026 and provided business updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are incredibly excited by the progress we made in the third quarter as we advanced EDIT-401, our potentially best-in-class in vivo gene editing medicine for hyperlipidemia, towards the clinic," said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. "The recent regulatory and ethics approval to initiate the Strive study in Australia and new preclinical durability data presented at AHA represent important milestones for EDIT-401, and, more importantly, for patients living with hyperlipidemia. Backed by this momentum and our strong cash position, we look forward to executing on the Strive study and generating additional data in 2027."

EDIT-401

Editas received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) to initiate the Phase 1/2 Strive study of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.
The Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027.
The Company expects to complete enrollment in Part 1 of the Strive study, with topline safety and efficacy results from Part 1 available in the second half of 2027.
Editas shared new EDIT-401 preclinical data in an oral presentation at the American Heart Association (AHA) Scientific Sessions 2026 in November demonstrating durable LDL-C lowering with EDIT-401 and further supporting its potential as a transformative, one-time treatment for people living with hyperlipidemia. Key data presented included:
LDL-C reduction of ≥90 percent with EDIT-401 was maintained over 10 months in an ongoing study in non-human primates (NHPs).
EDIT-401 achieved ~90 percent mean Lp(a) and ApoB reductions, which was maintained over three months in an ongoing study in NHPs.
Consistent safety profile with targeted delivery to the liver, transient elevations in LFTs, no histopathologic findings, and no evidence of genotoxicity in relevant primary human cells.

Corporate & Business Development Updates

In October, Editas presented two posters at the 33rd Annual European Society of Gene and Cell Therapy (ESGCT) Congress with preclinical data demonstrating robust in vivo delivery of mRNA to targeted T-cells with the Company’s novel, scalable platform for targeted lipid nanoparticle (tLNP) extrahepatic delivery, as well as data highlighting how platform-driven LNP process development can accelerate development timelines, mitigate scale-up risk, and effectively bridge discovery-stage innovation with the clinic, enabling the next generation of in vivo genetic medicines.

In September, Editas announced the appointment of Dan Ory, M.D., as Chief Medical Officer. With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will oversee the Company’s clinical development strategy and operations as Editas advances EDIT-401 into the clinic, while supporting the progression of the company’s broader pipeline.

As part of the Company’s collaboration agreement with Bristol Myers Squibb, a second IND/CTA was accepted for an alpha-beta T cell medicine, triggering a milestone payment to Editas. BMS will advance this second collaboration product, BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy, in a Phase 1 clinical study evaluating its safety and tolerability in participants with clear cell renal cell carcinoma, the most common form of kidney cancer. Editas developed the Cas12a gene editing technology used to engineer the CAR-T cells.

Upcoming Events

Editas Medicine plans to participate in the following investor event:

9th Annual Evercore Healthcare Conference
Format: Fireside Chat
Date: November 30, 2026
Time: 3:25 p.m. ET
Location: Coral Gables, FL

To access a live webcast of the Fireside Chat, please visit the "Investors" section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.

Third Quarter 2026 Financial Results

Cash, cash equivalents, and marketable securities as of September 30, 2026, were $190.2 million compared to $146.6 million as of December 31, 2025. The Company expects that its existing cash, cash equivalents, and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2028.
For the three months ended September 30, 2026, net loss attributable to common stockholders was $23.4 million, or $0.15 per share, compared to net loss of $25.1 million, or $0.28 per share, for the same period in 2025.
Collaboration and other research and development revenues increased to $10.4 million for the three months ended September 30, 2026, compared to $7.5 million for the same period in 2025. The increase was primarily attributable to revenue recognized in connection with clinical development milestones achieved by a strategic partner.
Research and development expenses increased by $1.4 million to $21.2 million for the three months ended September 30, 2026, compared to $19.8 million for the same period in 2025. The increase was primarily related to higher sublicense and license fees as well as increased costs associated with the continued development of EDIT-401. These increases were partially offset by lower employee-related costs and external research and development costs.
General and administrative expenses increased by $1.2 million to $13.5 million for the three months ended September 30, 2026, compared to $12.3 million for the same period in 2025. The increase was primarily attributable to higher intellectual property and patent-related fees due to increased legal activity related to intellectual property defense.

About EDIT-401
EDIT-401 is an experimental, potentially best-in-class in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. This targeted approach has demonstrated a favorable preclinical profile in both efficacy data and tolerability and supports the potential of EDIT-401 to deliver meaningful clinical outcomes for patients underserved by current lipid-lowering therapies.

About Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.

(Press release, Editas Medicine, NOV 9, 2026, View Source [SID1234674502])

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results

On November 9, 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, reported a business update and announced results for the quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform," said Thijs Spoor, Perspective’s Chief Executive Officer. "With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field."

Recent Program Updates

Bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs) and meningioma

Updated data were presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 and the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium showing strong clinical efficacy data. Read our complete NANETS press release here, and view our NANETS presentation on the Company’s website.

Enrollment in Cohort 4 has been completed. As of October 30, 2026, Cohort 4 of the dose-finding study for NETS closed for recruitment with 20 patients enrolled. The meningioma cohort remains open for recruitment with two patients treated as of October 30, 2026.

Pre-Phase 3 activities are progressing. We are targeting an end-of-Phase 2 meeting with the FDA in 1Q 2027.

European orphan medicinal product designation granted in July 2026 for the treatment of gastroenteropancreatic (GEP)-NETs.
Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma:

Data with longer follow-up were presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting showing strong, durable disease control in heavily pre-treated patients. Read our complete SITC (Free SITC Whitepaper) press release here, and view our SITC (Free SITC Whitepaper) poster on the Company’s website.

Recruiting more patients to corroborate encouraging monotherapy findings. As of October 30, 2026, 12 patients have been treated in a monotherapy cohort allowing up to a cumulative 9 mCi (333 MBq), administered in three treatments of 3.0 mCi every eight weeks. Five patients have been treated since the cohort reopened during 3Q 2026; by mid-2027, they are expected to reach at least 24 weeks of follow-up. This cohort remains open for enrollment.
PSV359 in FAP-α-positive solid tumors

Study progressing. This dose-finding study progressed into the third dose cohort, with a cumulative dose of 24 mCi administered in up to four treatments every eight weeks during 2Q 2026; as of September 30, 2026, 17 patients had been treated across the three cohorts. The next clinical update is planned in 2027.

Fast Track designation granted. In October 2026, the FDA granted PSV359 Fast Track Designation for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors. In September 2026, we entered into a clinical trial collaboration and supply agreement with Merck to support potential evaluation of PSV359 in combination with Keytruda (pembrolizumab) for certain types of lung and colorectal cancers.
Manufacturing: We expect construction to be completed at the Chicago metro site in early 2027.

Third Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of September 30, 2026, were approximately $202 million as compared to approximately $145 million as of December 31, 2025. We believe our cash, cash equivalents, and short-term investments are sufficient to fund our current planned clinical milestones and operational investments into 2028.

Research and development expenses were $26.1 million for the three months ended September 30, 2026, compared to $20.3 million for the three months ended September 30, 2025.

General and administrative expenses were $8.3 million for the three months ended September 30, 2026, compared to $7.7 million for the three months ended September 30, 2025.

Net loss for the three months ended September 30, 2026, was $32.4 million, or $0.27 per basic and diluted share, compared to a net loss of $26.0 million, or $0.35 per basic and diluted share, for the same period in 2025.

(Press release, Perspective Therapeutics, NOV 9, 2026, View Source [SID1234674518])

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

On November 9, 2026 ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, reported financial results for the third quarter ended September 30, 2026, and highlighted recent Company progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Enrollment remains on track for our global Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients. While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies. We are conducting a detailed review of the FURVENT study to better understand the totality of the data.," said Bing Yao, Ph.D., CEO of ArriVent. "Our antibody-drug conjugate (ADC) portfolio is also advancing, with initial ARR-217 data showing promising antitumor activity and a manageable safety profile in colorectal cancer. In addition, we dosed the first patient in a Phase 1 study of ARR-002. We are encouraged by the momentum across our pipeline and excited about the opportunity to advance these programs toward new potential treatment options for patients with significant unmet needs."

Third Quarter 2026 and Recent Highlights

Firmonertinib

· Continued Enrollment in Global Pivotal Phase 3 ALPACCA in PACC-Mutant NSCLC. The ALPACCA study is evaluating firmonertinib 240 mg against investigator’s choice of osimertinib or afatinib in first line patients with EGFR PACC mutant NSCLC. The study builds on encouraging Phase 1b FURTHER findings and includes an interim analysis of objective response rate to support a potential accelerated approval pathway, with PFS assessed for potential full approval.

· Reported Phase 3 FURVENT Results and Evaluating Next Steps. FURVENT did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). At 240 mg, firmonertinib demonstrated median PFS of 11.0 months versus 9.5 months with chemotherapy (HR 0.75; p=0.0654), a confirmed objective response rate by BICR of 60% versus 33%, and a safety profile consistent with prior studies. The Company is reviewing the full dataset, including differences between BICR and investigator-assessed PFS in the chemotherapy arm, to inform potential next steps.

ADC Pipeline

· Presented Phase 1 ARR-217 Data at ESMO (Free ESMO Whitepaper). Preliminary Phase 1 data for ARR-217 (MRG007), a CDH17-targeted ADC being developed in partnership with Lepu Biopharma, was presented in a late breaking rapid oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026. In evaluable patients with colorectal cancer treated at 6 mg/kg, the objective response rate, including confirmed and unconfirmed responses, was 44.8% and the disease control rate was 93.1%. Adverse events were predominantly low-grade gastrointestinal and hematologic toxicities. Phase 1b dose optimization and expansion are ongoing.

· Advanced ARR-002 into Clinical Development. Dosed the first patient in the U.S. Phase 1a/1b first-in-human study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC. The dose-escalation and expansion study is evaluating safety, dosing and early signals of efficacy in patients with advanced or metastatic ovarian or endometrial cancer.

Corporate

· Strengthened Clinical Leadership. Announced Dr. Priti Patel, M.D., M.S., as Chief Medical Officer. Dr. Patel brings extensive experience, in particular late-stage development experience, in both large pharmaceutical and emerging biotech in global oncology development including AstraZeneca, Acerta and Onyx Pharmaceuticals. Prior to joining ArriVent, Dr. Patel served as Chief Medical Officer at Neoleukin Therapeutics and Vice President, Head of Hematology Clinical Development at AstraZeneca.

· Retirement of Dr. Stuart Lutzker. Stuart Lutzker, M.D., Ph.D., a co-founder of ArriVent, announced his retirement. Over the past five years, Dr. Lutzker served as the President of Research and Development and Board member. During his tenure, Dr. Lutzker led the research and development team and was the architect of our ADC pipeline including advancing ARR-217 and ARR-002 into the clinic. "Dr. Lutzker has been the driving force behind our R&D vision," said Dr. Yao. "We are deeply grateful for his unwavering commitment and passion in advancing new therapies for patients. We thank him for all his contributions."

Upcoming Milestones

· Firmonertinib update. We plan to provide an update on firmonertinib in the first quarter of 2027 around the review of the FURVENT study.

· Phase 1b Data for ARR-217. Phase 1b dose optimization data for ARR-217 in late line colorectal cancer are expected in the first half of 2027, and ARR-217 combination data with bevacizumab as well as combination data with chemotherapy are expected in the second half of 2027.

2026 Financial Results

· As of September 30, 2026, the Company had cash and investments of $393.2 million, which is expected to fund operations to mid-2028.

· Net cash used in operations was $122.2 million and $129.9 million for the nine months ended September 30, 2026 and 2025, respectively.

· Research and development expenses were $118.9 million and $121.2 million for the nine months ended September 30, 2026 and 2025, respectively.

· General and administrative expenses were $28.3 million and $17.5 million for the nine months ended September 30, 2026 and 2025, respectively.

· Net loss was $133.5 million and $130.8 million for the nine months ended September 30, 2026 and 2025, respectively.

(Press release, ArriVent Biopharma, NOV 9, 2026, View Source [SID1234674463])

Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement

On November 9, 2026 Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, reported key highlights for its third quarter 2026 financial performance and business update conference call at 11:30 a.m. Eastern Time today, following the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will explain the scientific and clinical rationale for the Company’s CD228V agreement with Pfizer Inc. ("Pfizer"), the proposed transaction between its wholly owned subsidiary, SkinJect, Inc. ("SkinJect"), and an undisclosed special purpose acquisition company ("SPAC") (the "Transaction" or the "Business Combination") and the Company’s approach to capital efficiency.

Medicus’ strategy is to concentrate incremental development investment on CD228V, pursue a separate public listing and dedicated financing for SkinJect and preserve Teverelix’s readiness for partnering. The Company believes this approach can advance its precision oncology focus while preserving Medicus shareholders’ participation in the potential value of its broader portfolio.

Conference Call Details

Date and time: Monday, November 9, 2026, at 11:30 a.m. ET

Dial-in (U.S./Canada, toll-free): 1-833-890-6070

Dial-in (international): 1-412-504-9736

Webcast: Access the live webcast

Participants will include Raza Bokhari, MD, Executive Chairman and Chief Executive Officer; Carolyn Bonner, President and Chief Financial Officer; and Faisal Mehmud, MD, Chief Medical Officer.

CD228V Agreement Rationale, Melanoma Focus and ADC Opportunity

Dr. Raza Bokhari, Executive Chairman and CEO, is expected to describe how Medicus’ review of the clinical evidence for the predecessor molecule, SGN-CD228A, Pfizer’s refinement of the ADC construct and a focused initial development strategy informed the Company’s decision to enter the CD228V co-development and license agreement.

Clinical foundation. The decision was informed by Medicus’ review of clinical data from Seagen’s open-label Phase 1 study of SGN-CD228A, which enrolled 88 patients with advanced solid tumors, including melanoma and non-small cell lung cancer. This data provided preliminary clinical observations and insights into the CD228 target, safety and biomarkers. Detailed findings from that study have not yet been publicly disclosed.

Construct rationale. CD228V (PF-08046031) is a second-generation, clinical-stage antibody-drug conjugate directed against CD228, also known as melanotransferrin. The molecule uses Pfizer’s established vedotin linker-payload platform, with changes to the linker and the amount of payload carried by each antibody. Medicus understands that these refinements were designed to improve the balance between drug exposure, tolerability and anti-tumor activity. Vedotin technology has clinical and regulatory precedent in FDA-approved ADC therapies.

Focused melanoma strategy. Medicus intends to prioritize melanoma that has relapsed, become refractory or resisted immunotherapy. Based on its assessment of the predecessor clinical evidence from SGN-CD228A and the potential benefit of Pfizer’s linker-payload reconstruction, the Company believes CD228V has the potential to achieve an objective response rate exceeding 30% in melanoma. This potential remains to be demonstrated in clinical trials of CD228V. Any future monotherapy registration strategy would depend on durable responses, an acceptable safety profile and applicable regulatory requirements.

The ADC opportunity. Medicus is emerging as part of approximately 30 clinical-stage ADC developers across the globe. At one end of this field are established companies with approved products and extensive development capabilities; at the other are companies with programs still in clinical research and development. The CD228V agreement also places Medicus amongst a handful of companies advancing Seagen-linked ADC assets through Pfizer collaborations. The rights, economics and clinical maturity of those relationships differ.

The Company believes that worldwide rights, a defined initial clinical objective and evidence generated through development could support future licensing, co-development and other strategic opportunities.

Rationale for the Proposed SkinJect SPAC Transaction

The proposed SkinJect Transaction is intended to establish a separately listed company with its own access to public capital markets and dedicated financing for Gorlin syndrome development, while Medicus seeks to retain majority economic and voting ownership of the combined company. The Company believes this structure could support SkinJect’s advancement while allowing Medicus to concentrate incremental investment on precision oncology.

The non-binding letter of intent ("LOI") with the SPAC contemplates an approximately $135 million pre-money enterprise valuation for SkinJect. Under the proposed terms, the SPAC would acquire 100% of SkinJect in exchange for newly issued common shares of the combined company. Concurrent equity financing is contemplated at closing of the Transaction to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential New Drug Application (NDA).

The Company currently projects approximately $3 million over the next two years for that program. This is a projected program cost, subject to execution and regulatory requirements. Medicus will continue allocating essential resources to maintain program readiness as the proposed Transaction progresses.

The Company currently anticipates completing the proposed Transaction during the first half of 2027. The LOI is non-binding, and there can be no assurance that definitive agreements will be signed, financing will be secured, Medicus will retain majority ownership, or the Transaction will close within that timeframe or at all.

Capital Efficiency and Portfolio Execution

Medicus intends to align organizational costs and development spending with its portfolio priorities. Incremental capital will be directed toward CD228V, with essential resources allocated to maintain Teverelix’s value and partnering readiness and pursue the proposed SkinJectTransaction. Management anticipates a substantial reduction in operating expenses in the coming quarters.

For Teverelix, Medicus is seeking partners with the capabilities and resources to advance opportunities in urology, advanced prostate cancer and women’s health. The optimized prostate cancer protocol remains subject to FDA feedback. Maintaining program readiness while pursuing partnerships is intended to preserve the asset’s potential value within the Company’s capital allocation strategy.

Financial Performance Supporting the Strategic Update

Ms. Carolyn Bonner, President and CFO, is expected to describe the Company’s financial results for the third quarter and nine months ended September 30, 2026. During the nine-month period, Medicus raised approximately $42.6 million through equity and secured debt financings, net of issuance costs. After approximately $6.4 million in debt repayments, net cash provided by financing activities was $36.2 million. This capital supported the CD228V license and development across the portfolio.

Selected financial results in U.S. dollars in millions for periods ended September 30

Metric Q3 2026 Q3 2025 Nine months
2026 Nine months
2025
Operating expenses 14.5 15.4 34.5 26.6
Net loss (15.2) (16.0) (35.9) (27.3)
Nine-month operating expenses included $9.6 million of research and development expense and a $10.0 million acquired in-process research and development charge.

On September 30, 2026, Medicus held $5.0 million in cash and cash equivalents and $8.1 million in restricted cash, for a combined total of $13.1 million. Cash and cash equivalents on December 31, 2025, were $8.7 million.

(Press release, Medicus Pharma, NOV 9, 2026, View Source [SID1234674479])

Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

On November 9, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation who had received at least one prior line of therapy. The trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This press release features multimedia. View the full release here: View Source

The Phase 2 trial is ongoing, and the topline data include 42 patients with endometrioid endometrial cancer who had a median of 2 prior lines of therapy (range 1-4 lines). As of the October 30, 2026 efficacy data cut, confirmed objective responses were observed in 12 of the 36 efficacy-evaluable patients, for a confirmed objective response rate (ORR) of 33%. One additional patient had a partial response that could not be confirmed because the patient discontinued the study before a confirmatory scan, for an unconfirmed ORR of 36% (13 of 36). Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16). In the 42 treated patients, the preliminary Kaplan-Meier estimated median progression-free survival (PFS) was 7.4 months (95% CI 5.3-NR), and the 6-month PFS rate was 62% (95% CI 43%-75%); 16 patients remained on treatment at the data cut.

"We believe these data support the multi-nodal PAM targeting hypothesis, whereby more complete inhibition of the pathway may drive durable responses and extend progression-free survival without the safety limitations of single-node inhibitors," said Anand Parikh, Co-Founder and Chief Executive Officer of Faeth. "Endometrial cancer has among the highest rates of PI3K pathway alterations of any cancer, yet no drug that targets the pathway is approved to treat it.

"In PIK-201, PIKTOR delivered a preliminary estimated median PFS of 7.4 months, which we believe compares favorably to the 3-4 months typical for salvage chemotherapy alone, or the 6-7 months observed with newer treatments including TOPO1-based ADCs." Mr. Parikh continued, "In our view, these preliminary data set PIKTOR apart. On the safety side, hyperglycemia and stomatitis were mostly low grade in a population in which nearly half of patients had diabetes or prediabetes and prophylactic steroid mouthwash was not required. We now plan to advance toward a Phase 3 trial, subject to regulatory alignment, with the goal of getting PIKTOR into the hands of patients as expeditiously as possible."

"We need more treatment options for patients whose advanced endometrial cancer has progressed after platinum chemotherapy and immunotherapy," said David Starks, MD, MPH, a PIK-201 and GOG Foundation principal investigator and Gynecologic Oncologist at Avera Cancer Institute, Sioux Falls, South Dakota. "I believe the response and progression-free survival data reported for PIKTOR with paclitaxel give physicians a reason to follow it closely. I am excited by the potential that this treatment could have for my patients."

Phase 2 FTH-PIK-201 Topline Clinical Data Highlights

Baseline characteristics

The open-label, single-arm Phase 2 trial (NCT06463028, GOG-3111) is evaluating patients with PIKTOR plus paclitaxel.
48% of patients had diabetes or pre-diabetes at baseline.
76% of patients had distant metastases, including liver and lung lesions.
Patients had a median of 2 prior lines of therapy (range 1 to 4), with 3 or more prior lines in 15 patients (36%).
All patients had been previously treated with taxane-based chemotherapy (100%), and prior immunotherapy was reported in 41 patients (98%).
Of the 42 treated patients, 6 were not evaluable for efficacy, having discontinued prior to the first post-baseline scan due to early disease progression (n=3) or non-treatment-related reasons (n=3).
Efficacy

As of the October 30, 2026 efficacy data cut:

The confirmed ORR was 33% (12 of 36 efficacy-evaluable patients). One additional patient had a partial response that could not be confirmed because the patient discontinued the study before a confirmatory scan, for an unconfirmed ORR of 36% (13 of 36).
Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16).
At the data cut, 9 of the 12 confirmed responders and 7 patients with a best response of stable disease remained on treatment. Several responses deepened over the course of therapy, including one patient who converted from stable disease to partial response after 20 months of treatment.
The disease control rate (DCR) was 83% (30 of 36), defined as the percentage of patients with a best overall response of complete response, partial response or stable disease.
In all 42 treated patients, the preliminary Kaplan-Meier estimated median PFS was 7.4 months (95% CI: 5.3 to NR), and the preliminary 6-month PFS rate was 62% (95% CI: 43% to 75%).
Safety

As of the October 23, 2026 safety data cut:

Two patients (5%) discontinued treatment due to a treatment-related adverse event (TRAE; headache, dizziness). There were no treatment-related deaths.
64% of patients had a grade 3 or higher TRAE. Neutropenia, a grouped term including neutropenia and decreased neutrophil count, occurred in 36% of patients overall and was the most frequent grade 3 or higher TRAE (26%).
Hyperglycemia TRAEs occurred in 5 of 42 patients (12%), and 1 patient (2%) had a grade 3 event. 48% of patients had diabetes or pre-diabetes at baseline.
Stomatitis TRAEs occurred in 21% of patients, and 1 patient (2%) had a grade 3 event. Patients did not receive steroid mouthwash prophylaxis.
Webcast details

Faeth will host a webcast today, November 9, 2026, at 8:00 a.m. ET to discuss the data. David Starks, MD, MPH, Gynecologic Oncologist at Avera Cancer Institute, Sioux Falls, South Dakota, will join management. To access the live webcast, click here. A replay will be available in the Events and Presentations (Events and Presentations — Faeth Therapeutics, Inc) section of Faeth’s corporate website.

(Press release, Faeth Therapeutics, NOV 9, 2026, View Source [SID1234674503])